Table 2. Mortality data from the CAPACITY study.

	Pifenidone# 2403 mg·day−1	Placebo¶	Hazard ratio (95% CI)+	p-value§
Overall
All-cause mortality	27 (8)	34 (10)	0.77 (0.47–1.28)	0.315
IPF-related mortalityƒ	18 (5)	28 (8)	0.62 (0.35–1.13)	0.117
On-treatment##
All-cause mortality	19 (6)	29 (8)	0.65 (0.36–1.16)	0.141
IPF-related mortalityƒ	12 (3)	25 (7)	0.48 (0.24–0.95)	0.030

Data are presented as n (%), unless otherwise stated. IPF: idiopathic pulmonary fibrosis; CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. ^#: n=345; ^¶: n=347; ⁺: based on the Cox-proportional hazard model; ^§: log-rank test (pirfenidone 2403 mg·day⁻¹ versus placebo); ^ƒ: assessed by the investigator, who remained blinded to treatment assignment; ^##: defined as the time from randomisation until 28 days after the last dose of study drug. Reproduced from [22] with permission from the publisher.